Medifocus Inc. announced that it has entered into an exclusive distribution agreement with Amos Gazit Ltd. to market and distribute the company's proven Prolieve® Thermodilatation System for the treatment of BPH in the territory of Israel. Prolieve® Thermodilatation is a proven innovation and is the only Third Generation TUMT uniquely combining microwave thermotherapy with a dilating balloon that compresses the prostatic urethra during treatment. Such tissue compression allows effective thermotherapy to be delivered at a lower microwave energy, which translates into better patient comfort and safety. Thermodilatation also assures a patent post-treatment prostatic urethra that contributes to a much lower post-treatment catheterization rate compared to other minimally invasive treatments for BPH. Prolieve® is a proven technology with over 100,000 cases performed in the U.S. alone. The Company's 10-year FDA post market study of 220 men treated with Prolieve® demonstrated long-term safety, efficacy, and durability with improved lower urinary tract symptoms, urinary flow rate, quality of life, and little or no sexual side effects compared to the untreated age-matched population at 5-year follow-ups.